MARKET

MLND

MLND

Millendo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.080
-0.010
-0.92%
After Hours: 1.080 0 0.00% 19:55 05/10 EDT
OPEN
1.070
PREV CLOSE
1.090
HIGH
1.110
LOW
1.050
VOLUME
1.91M
TURNOVER
--
52 WEEK HIGH
3.640
52 WEEK LOW
0.9181
MARKET CAP
20.57M
P/E (TTM)
-0.5581
1D
5D
1M
3M
1Y
5Y
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - NTEC, SNX, STAY, MX, MLND
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire · 4d ago
Is Millendo Therapeutics (NASDAQ:MLND) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 5d ago
BRIEF-Harpoon Therapeutics Says On April 23, Delaware Court Issued Memorandum Opinion
reuters.com · 04/26 12:34
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21)
Benzinga · 04/22 12:08
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 04/20 12:06
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 04/16 12:00
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14)
Benzinga · 04/15 11:49
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 04/14 11:51
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MLND. Analyze the recent business situations of Millendo Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MLND stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 7.94M
% Owned: 41.69%
Shares Outstanding: 19.04M
TypeInstitutionsShares
Increased
12
522.10K
New
5
1.23M
Decreased
13
1.10M
Sold Out
9
880.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.99%
Pharmaceuticals & Medical Research
-0.43%
Key Executives
Chairman/Executive Director
Julia Owens
President/Chief Executive Officer
Louis Arcudi
Chief Financial Officer/Chief Accounting Officer
Jennifer Minai-azary
General Counsel/Secretary
Tamara Joseph
Other
Christophe Arbet-Engels
Other
Thomas Hoover
Other
Ryan Zeidan
Director
Carol Gallagher
Independent Director
James Hindman
Independent Director
John Howe
Independent Director
Geoffrey Nichol
Independent Director
Carole Nuechterlein
No Data
About MLND
Millendo Therapeutics, Inc., formerly OvaScience, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing novel treatments for orphan endocrine diseases. The Company is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. It is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.

Webull offers kinds of Millendo Therapeutics Inc stock information, including NASDAQ:MLND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MLND stock methods without spending real money on the virtual paper trading platform.